Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 2, 2000, Pages 103-110

  Roberts, John D ^a   Poplin, Elizabeth A ^b   Tombes, Mary Beth ^a   Kyle, Brenda ^a   Spicer, Darcy V ^c   Grant, Steven ^a   Synold, Timothy ^d   Moran, Richard ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NONE

Author keywords

(6R) 5,10 dideaza 5,6,7,8 tetrahydrofolate; Folate antimetabolite; Lometrexol; Phase I trial

Indexed keywords

FOLINIC ACID; LOMETREXOL;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KIDNEY CANCER; LUNG CANCER; MALE; MELANOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER; SARCOMA; STOMACH CANCER; THROMBOCYTOPENIA;

EID: 0033966061     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050017     Document Type: Article

References (25)

1. 1. Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone L (1998) Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 16: 153
2. 2. Alati T, Worzalla J, Shih C, Bewley JR, Lewis S, Moran RG, Grindey G (1996) Augmentation of the therapeutic activity of lometrexol [(6R)-5,10-dideazatetrahydrofolate] by oral folic acid. Cancer Res 56: 2331
3. 3. Barredo J, Moran RG (1992) Determinants of antifolate cytotoxicity: folylpolyglutamate synthetase activity during cellular proliferation and development. Mol Pharmacol 42: 687
4. 4. Beardsley GP, Moroson BA, Taylor EC, Moran RG (1989) A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate, is a potent inhibitor of de novo purine synthesis. J Biol Chem 264: 328
5. 5. Boschelli DH, Webber S, Whiteley JM, Oronsky AL, Kerwar SS (1988) Synthesis and biological properties of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid. Arch Biochem Biophys 265: 43
6. 6. Cole JT, Gralla RJ, Karcinal CG, Rivera NP (1992) Lometrexol (DDATHF): phase I trial of a weekly schedule of this new antifolate. Proc Am Assoc Cancer Res 33: 2468
7. 7. Grindey GB, Alati T, Shih C (1991) Reversal of the toxicity but not the antitumor activity of lometrexol by folic acid. Proc Am Assoc Cancer Res 32: 324
8. 8. Kamen BA, Holcenberg JS, Turo K, Whitehead VM (1984) Methotrexate and folate content of erythrocytes in patients receiving oral vs intramuscular therapy with methotrexate. J Pediatr 104: 131
9. 9. Krakower GR, Kamen BA (1984) The reticulocyte rat: a model for analysis of methotrexate polyglutamate dynamics in situ. J Pharmacol Exp Ther 231: 43
10. 10. Kremer JM, Galivan J, Streckfuss A, Kamen B (1986) Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Arthritis Rheum 29: 832
11. 11. Laohavinij S, Wedge SR, Lind MJ, Bailey N, Humphreys A, Proctor M, Chapman F, Simmons D, Oakley A, Robson L, Gumbrell L, Taylor GA, Thomas HD, Boddy AV, Newell DR, Calvert AH (1996) Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Invest New Drugs 14: 325
12. 12. Mendelsohn LG, Shih C, Schultz RM, Worzalla JF (1996) Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Invest New Drugs 14: 287
13. 13. Muggia FM, Synold TW, Newman EM, Jeffers S, Leichman LP, Doroshow JH, Johnson K, Groshen S (1996) Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexol. J Natl Cancer Inst 88: 1495
14. 14. Nelson R, Butler F, Dugan W Jr, Davis-Land C, Stone M, Dyke R (1990) Phase I clinical trial of LY264618 (dideazatetrahydrofolic acid; DDATHF). Proc Am Soc Clin Oncol 9: 76
15. 15. Pohland RC, Alati R, Lantz RJ, Grindey GB (1994) Wholebody autoradiographic disposition and plasma pharmacokinetics of 5,10-dideazatetrahydrofolic acid in mice fed folic acid-deficient or regular diets. J Pharm Sci 83: 1396
16. 16. Ray MS, Muggia FM, Leichman CG, Grunberg SM, Nelson RL, Dyke RW (1993) Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst 85: 1154
17. 17. Sessa C, Jong J de, D'Incalci M, Hatty S, Pagani O, Cavilli F (1996) Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue. Clin Cancer Res 2: 1123
18. 18. Shih C, Grindey GB, Houghton PJ, Houghton JA (1998) In vivo antitumor activity of 5,10-dideazatetrahydrofolic acid (DDATHF) and its diastereomeric isomers. Proc Am Assoc Cancer Res 29: 283
19. 19. Smith SG, Lehman NL, Moran RG (1993) Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res 53: 5697
20. 20. Synold TW, Xi B, Newman EM, Muggia FM, Doroshow JH (1996) Simple and sensitive method for the quantitative analysis of lometrexol in plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 683: 245
21. 21. Synold TW, Newman EM, Carroll M, Muggia FM, Groshen S, Johnson K, Doroshow JH (1998) Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. Clin Cancer Res 4: 2349
22. 22. Taber LD, O'Brien P, Bowsher RR, Sportsman JR (1991) Competitive particle concentration fluorescence immunoassay for measuring 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) in serum. Clin Chem 37: 254
23. 23. Taylor EC (1990) New pathways from pteridines. Design and synthesis of a new class of potent and selective antitumor agents. J Heterocycl Chem 27: 1
24. 24. Wedge SR, Laohavinij S, Taylor G, Boddy A, Calvert AH, Newell DR (1995) Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement. Clin Cancer Res 1: 1479
25. 25. Young CW, Currie VE, Muindi JF, Saltz LB, Pisters KMW, Esposito AJ, Dyke RW (1992) Improved clinical tolerance of lometrexol with oral folic acid. Proc Am Assoc Cancer Res 33: 406